Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
10 05 2022
Historique:
entrez: 10 5 2022
pubmed: 11 5 2022
medline: 14 5 2022
Statut: ppublish

Résumé

Chronic obstructive pulmonary disease (COPD) is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of deterioration of lung function. In 2020 it was estimated that approximately 6% of US adults had been diagnosed with COPD. Chronic lower respiratory disease, composed mainly of COPD, is the sixth leading cause of death in the US. To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update that focused on targeted key questions for benefits and harms of screening for COPD in asymptomatic adults and treatment in screen-detected or screen-relevant adults. Asymptomatic adults who do not recognize or report respiratory symptoms. Using a reaffirmation process, the USPSTF concludes with moderate certainty that screening for COPD in asymptomatic adults has no net benefit. The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation).

Identifiants

pubmed: 35536260
pii: 2791924
doi: 10.1001/jama.2022.5692
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

1806-1811

Commentaires et corrections

Type : SummaryForPatientsIn
Type : CommentIn

Auteurs

Carol M Mangione (CM)

University of California, Los Angeles.

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Wanda K Nicholson (WK)

University of North Carolina at Chapel Hill.

Michael Cabana (M)

Albert Einstein College of Medicine, New York, New York.

Aaron B Caughey (AB)

Oregon Health & Science University, Portland.

David Chelmow (D)

Virginia Commonwealth University, Richmond.

Tumaini Rucker Coker (TR)

University of Washington, Seattle.

Esa M Davis (EM)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Katrina E Donahue (KE)

University of North Carolina at Chapel Hill.

Carlos Roberto Jaén (CR)

University of Texas Health Science Center, San Antonio.

Martha Kubik (M)

George Mason University, Fairfax, Virginia.

Li Li (L)

University of Virginia, Charlottesville.

Gbenga Ogedegbe (G)

New York University, New York, New York.

Lori Pbert (L)

University of Massachusetts Medical School, Worcester.

John M Ruiz (JM)

University of Arizona, Tucson.

James Stevermer (J)

University of Missouri, Columbia.

Chien-Wen Tseng (CW)

University of Hawaii, Honolulu.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH